Medicare, the U.S. health plan for older Americans, will cover the cost of screening for hepatitis C, a decision that may further open the government’s wallet for Gilead Sciences Inc.’s $84,000 cure for the disease.
Genzyme Corp.’s chief executive officer, Henri A. Termeer , will leave his post of 26 years after Sanofi-Aventis SA closes its $20.1 billion purchase of his company. He may not be out of a job for long.
Human Genome Sciences Inc. investors betting on a sweetened bid from GlaxoSmithKline Plc stand to reap a 13 percent return, even as their expectations of securing America’s biggest price increase diminish.
Affymax Inc. fell as much as 85 percent after the drugmaker and partner Takeda Pharmaceutical Co. voluntarily recalled an anemia treatment for kidney dialysis patients after reports of three fatal reactions.
Affymax Inc. rose the most in seven months after the biotechnology company and partner Takeda Pharmaceutical Co. agreed to supply their anemia drug Omontys to Fresenius Medical Care AG for use in dialysis patients.